Spotlight On High Growth Tech Stocks For December 2024
| ALNY Stock | USD 235.31 0.70 0.30% |
Slightly above 56% of Alnylam Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that many traders are alarmed. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Alnylam |
As global markets continue to reach record highs, with the small-cap Russell 2000 Index hitting a notable intraday peak, investor sentiment appears buoyed by recent domestic policy developments and geopolitical events. In this context of robust market performance and economic shifts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amid changing trade dynamics and economic indicators.
Read at finance.yahoo.com
 |
Alnylam Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
44
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Alnylam Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Alnylam Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Alnylam Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Alnylam Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alnylam Pharmaceuticals Fundamental Analysis
We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Alnylam Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Alnylam Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Alnylam Pharmaceuticals Related Equities
| PRME | Prime Medicine, | 5.04 | ||||
| HCWB | HCW Biologics | 4.65 | ||||
| NTLA | Intellia Therapeutics | 2.19 | ||||
| SEER | Seer | 1.76 | ||||
| NRIX | Nurix Therapeutics | 1.07 | ||||
| MNOV | MediciNova | 0.47 | ||||
| BEAM | Beam Therapeutics | 1.86 | ||||
| PASG | Passage Bio | 14.93 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.